Concepedia

Publication | Open Access

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies

DOIFull Paper Access

134

Citations

26

References

2018

Year

Norbert Vey, Lionel Karlin, Sophie Sadot‐Lebouvier, Florence Broussais, Dominique Berton-Rigaud, Jérôme Rey, Aude Charbonnier, Delphine Marie, Pascale André, Carine Paturel,
Oncotarget

Abstract

This phase 1 trial demonstrated the satisfactory safety profile of lirilumab up to doses that enable full and sustained blockade of KIR.

References

YearCitations

Page 1